These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 19850405)

  • 1. Geldanamycin and its anti-cancer activities.
    Fukuyo Y; Hunt CR; Horikoshi N
    Cancer Lett; 2010 Apr; 290(1):24-35. PubMed ID: 19850405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geldanamycin-induced PCNA degradation in isolated Hsp90 complex from cancer cells.
    Wang X; Heuvelman DM; Carroll JA; Dufield DR; Masferrer JL
    Cancer Invest; 2010 Jul; 28(6):635-41. PubMed ID: 20394503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
    Powers MV; Workman P
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation.
    Koga F; Xu W; Karpova TS; McNally JG; Baron R; Neckers L
    Proc Natl Acad Sci U S A; 2006 Jul; 103(30):11318-22. PubMed ID: 16844778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
    Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T; Keum G; Pae AN
    Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J; Pham NA; Cao MP; Hedley DW
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
    Kurashina R; Ohyashiki JH; Kobayashi C; Hamamura R; Zhang Y; Hirano T; Ohyashiki K
    Cancer Lett; 2009 Oct; 284(1):62-70. PubMed ID: 19464103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Heat shock protein 90: novel target for cancer therapy].
    Chen Y; Ding J
    Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives.
    Onuoha SC; Mukund SR; Coulstock ET; Sengerovà B; Shaw J; McLaughlin SH; Jackson SE
    J Mol Biol; 2007 Sep; 372(2):287-97. PubMed ID: 17662999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
    Moser C; Lang SA; Stoeltzing O
    Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
    Chiosis G; Caldas Lopes E; Solit D
    Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
    Stravopodis DJ; Margaritis LH; Voutsinas GE
    Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Hsp90-specific inhibitor geldanamycin selectively disrupts kinase-mediated signaling events of T-lymphocyte activation.
    Schnaider T; Somogyi J; Csermely P; Szamel M
    Cell Stress Chaperones; 2000 Jan; 5(1):52-61. PubMed ID: 10701840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking the chaperone kinome pathway: mechanistic insights into a novel dual inhibition approach for supra-additive suppression of malignant tumors.
    Grover A; Shandilya A; Agrawal V; Pratik P; Bhasme D; Bisaria VS; Sundar D
    Biochem Biophys Res Commun; 2011 Jan; 404(1):498-503. PubMed ID: 21144839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Geldanamycin inhibits tyrosine phosphorylation-dependent NF-kappaB activation.
    Crèvecoeur J; Merville MP; Piette J; Gloire G
    Biochem Pharmacol; 2008 Jun; 75(11):2183-91. PubMed ID: 18455150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
    Kamal A; Thao L; Sensintaffar J; Zhang L; Boehm MF; Fritz LC; Burrows FJ
    Nature; 2003 Sep; 425(6956):407-10. PubMed ID: 14508491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.
    Clarke PA; Hostein I; Banerji U; Stefano FD; Maloney A; Walton M; Judson I; Workman P
    Oncogene; 2000 Aug; 19(36):4125-33. PubMed ID: 10962573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Geldanamycin, an hsp90/GRP94-binding drug, induces increased transcription of endoplasmic reticulum (ER) chaperones via the ER stress pathway.
    Lawson B; Brewer JW; Hendershot LM
    J Cell Physiol; 1998 Feb; 174(2):170-8. PubMed ID: 9428803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
    Workman P; Burrows F; Neckers L; Rosen N
    Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.